Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Medarex's secondary cataract product enters phase III

Dec. 19, 1997

Pharmacyclics grants Alcon rights to Lu-Tex

Dec. 19, 1997

InSite Vision brings its once-daily glaucoma treatment to clinical trials

Dec. 8, 1997

Alcon compounds with dual antioxidant/cysteine prodrug properties

Dec. 8, 1997

Spotlight on carbonic anhydrase inhibitors for glaucoma

Nov. 25, 1997

KeraVision Ring evaluated in extended phase III trial

Nov. 21, 1997

Promising phase III results reported for KeraVision ring

Nov. 4, 1997

German launch for Xalatan

Oct. 23, 1997

Patient recruitment for verteporfin phase III trials exceeds goals

Sep. 30, 1997

Lotemax deemed approvable by FDA

Sep. 26, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...